TGFB1 and head and neck squamous cell carcinoma: Ultimately, TGF-β inhibition remains a potentially viable approach for the management of recurrent and metastatic HNSCC; however, gaps in knowledge regarding patient stratification will continue to limit its applicability to clinical practice.